Rosuvastatin Dosing and Contraindications
Rosuvastatin should be initiated at 5-40 mg once daily as a single dose, taken at any time of day with or without food, with the specific dose determined by the patient's indication (primary vs. secondary prevention), baseline LDL-C level, and cardiovascular risk profile 1.
Standard Dosing Regimens
Adult Patients
- Dosage range: 5-40 mg orally once daily 1
- Administration: Single dose at any time of day, with or without food; swallow tablets whole 1
- Monitoring: Assess LDL-C as early as 4 weeks after initiation and adjust dosage accordingly 1
For primary prevention (patients without established CVD), 10 mg is the most commonly prescribed dose (65% of cases), while for secondary prevention, 20 mg is preferred (54.3% of cases) 2. This aligns with the concept that higher-risk patients require more intensive lipid-lowering therapy.
Pediatric Patients
- HeFH (ages 8-10 years): 5-10 mg once daily 1
- HeFH (ages ≥10 years): 5-20 mg once daily 1
- HoFH (ages ≥7 years): 20 mg once daily 1
Special Population Dosing Adjustments
Asian Patients
Initiate at 5 mg once daily due to increased rosuvastatin plasma concentrations in this population 1. When treating Asian patients not adequately controlled at doses up to 20 mg daily, carefully weigh risks versus benefits before escalating further.
Severe Renal Impairment
In patients with CrCl <30 mL/min/1.73 m² not on hemodialysis: Start at 5 mg once daily and do not exceed 10 mg once daily 1. No dosage adjustments are needed for mild-to-moderate renal impairment.
Critical Drug Interaction Dose Modifications
The following concomitant medications require specific rosuvastatin dose limitations 1:
Do not exceed 5 mg once daily with:
- Cyclosporine
- Darolutamide
Do not exceed 10 mg once daily with:
- Teriflunomide
- Enasidenib
- Capmatinib
- Regorafenib
- Protease inhibitors (atazanavir/ritonavir, lopinavir/ritonavir)
- Multiple HCV antivirals (simeprevir, dasabuvir/ombitasvir/paritaprevir/ritonavir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir)
Do not exceed 20 mg once daily with:
- Fostamatinib
- Febuxostat
Avoid concomitant use (or use with extreme caution):
- Gemfibrozil: If must use together, initiate at 5 mg once daily and do not exceed 10 mg once daily 1
- Tafamidis: If must use together, initiate at 5 mg once daily and do not exceed 20 mg once daily 1
- Sofosbuvir/velpatasvir/voxilaprevir and ledipasvir/sofosbuvir: Concomitant use not recommended 1
Calcium Channel Blocker Interactions
Rosuvastatin has minimal interactions with calcium channel blockers 3. Unlike simvastatin and lovastatin (which are CYP3A4 substrates), rosuvastatin can be safely coadministered with amlodipine, diltiazem, and verapamil without dose restrictions, making it a preferred choice when CCBs are needed 3.
Important Administration Details
When taking with aluminum/magnesium hydroxide antacids: Administer rosuvastatin at least 2 hours before the antacid 1.
If a dose is missed: Do not take an extra dose; simply resume with the next scheduled dose 1.
Clinical Efficacy by Dose
The evidence demonstrates dose-dependent LDL-C reductions 4, 5, 6:
- 5 mg: 42% LDL-C reduction
- 10 mg: 52% LDL-C reduction
- 20 mg: 55-60% LDL-C reduction
- 40 mg: 63% LDL-C reduction
Rosuvastatin 5 mg is more effective than atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg for LDL-C reduction 4. When combined with ezetimibe, rosuvastatin provides 60-75% LDL-C reductions 7, 8.
Safety Profile
Rosuvastatin 10-40 mg demonstrates a safety profile similar to other widely used statins 5. In clinical experience:
- Myopathy: ≤0.03% of patients receiving 10-40 mg 5
- Rhabdomyolysis: No cases reported at 10-40 mg doses 5
- Clinically significant ALT elevations: 0.2% (comparable to other statins) 5
- Adverse events in real-world use: 0.4% (leg pain, nausea, muscle cramps, myalgia) 2
Guideline Context for Statin Use
The 2016 USPSTF recommends statin therapy for adults aged 40-75 years without CVD who have ≥1 CVD risk factor and a calculated 10-year CVD event risk ≥7.5% 9. The ACC/AHA guidelines recommend moderate-to-high intensity statins based on 10-year risk, with rosuvastatin 10-40 mg classified as high-intensity therapy 9.